Lyndra Littles

Lyndra Therapeutics Doses First Clinical Trial Participant in Pivotal Study of Oral Weekly Risperidone (LYN-005) for Schizophrenia and Schizoaffective Disorder

Retrieved on: 
Tuesday, May 9, 2023
Biotechnology, Mental Health, Health, Pharmaceutical, Clinical Trials, Injection, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Donald, Hospital, Schizophrenia, Clinical trial, Medicine, Schizoaffective disorder, Bipolar I disorder, Risperidone, Patient, Clinical research, Psychiatry, Therapy, Mental health, Caregiver, Safety, Pharmaceutical industry, Lyndra Littles

Lyndra Therapeutics, a clinical-stage biopharmaceutical company working to make daily pills a thing of the past, today announced it has dosed the first participant in its pivotal clinical trial investigating oral weekly risperidone (LYN-005).

Key Points: 
  • Lyndra Therapeutics, a clinical-stage biopharmaceutical company working to make daily pills a thing of the past, today announced it has dosed the first participant in its pivotal clinical trial investigating oral weekly risperidone (LYN-005).
  • Lyndra is developing LYN-005 to provide a new treatment option for patients living with schizophrenia, schizoaffective disorder and bipolar I disorder.
  • Lyndra’s LYNX™ drug delivery platform is designed to enable a week-long dose of risperidone to be delivered in a single oral capsule.
  • The oral daily form of risperidone is one of the most prescribed treatments for people living with schizophrenia and bipolar I disorder.

Lyndra Therapeutics Announces New Board Members and Chief Technology Officer

Retrieved on: 
Thursday, January 5, 2023
Mental Health, Health, Infectious Diseases, Research, Science, Pharmaceutical, Biotechnology, Lyndra Littles, Bill & Melinda Gates Foundation, Partnership, Bain, Therapy, Private law, Hotel manager, Bill, Interim, Global health, MBA, Arnold & Porter, Medicine, Arnold, Bain & Company, Management, Pharmaceutical industry

“We are pleased to have these three industry-leading executives join the team,” said Dr. Patricia Hurter, CEO of Lyndra Therapeutics.

Key Points: 
  • “We are pleased to have these three industry-leading executives join the team,” said Dr. Patricia Hurter, CEO of Lyndra Therapeutics.
  • “Kyle brings a depth of experience in all facets of technical operations, strategy, product innovation, supply chain and manufacturing.
  • The addition of Madonick and Singh to Lyndra’s Board of Directors brings relevant expertise in global healthcare law, strategy and operations to the table.
  • “Lyndra’s unique delivery platform can be applied to nearly any medication and therapeutic area, transforming the patient and caregiver experience,” said Amy Schulman, co-founder of Lyndra Therapeutics and executive chair of the company’s Board of Directors.

Lyndra Therapeutics President and Chief Operations Officer Jessica Ballinger Named to National Small Business Association (NSBA) Leadership Council

Retrieved on: 
Thursday, June 16, 2022
Professional Services, Mental Health, Health, Small Business, Neurology, Pharmaceutical, Biotechnology, Thought disorder, NSBA, CNS, Public health, COVID-19, GMP, Bill, Science, Schizophrenia, AbbVie, Climate Leadership Council, Congress, Central nervous system, Gilead Sciences, Opioid use disorder, Medicine, Buprenorphine, Malaria, Small business, Ivermectin, DE, Multimedia, Therapy, Bill & Melinda Gates Foundation, NIH, Pharmaceutical industry, Management, Lyndra Littles

Lyndra Therapeutics, a clinical-stage biopharmaceutical company working to make daily pills a thing of the past, today announced that President and Chief Operations Officer Jess Ballinger has been named to the National Small Business Association (NSBA) Leadership Council, joining other advocates from across the country as they work to promote the interests of small business to policymakers in Washington, D.C.

Key Points: 
  • Lyndra Therapeutics, a clinical-stage biopharmaceutical company working to make daily pills a thing of the past, today announced that President and Chief Operations Officer Jess Ballinger has been named to the National Small Business Association (NSBA) Leadership Council, joining other advocates from across the country as they work to promote the interests of small business to policymakers in Washington, D.C.
  • Im honored to join the NSBA Leadership Council and to be able to bring my passion for science and DE&I to this team of expert small-business leaders.
  • I am proud to have Jess Ballinger as part of our Leadership Council, stated NSBA President and CEO Todd McCracken.
  • Lyndra is focused on commercializing therapies in central nervous system (CNS) disorders , which would most benefit from dramatically reduced dosing frequency.